Effects of Intravitreal Injection Bevacizumab in Posterior Segment Vasculopathies - A Clinical Study

Dr. Abhiraj Mane | Dr. V. H. Karambelkar | Dr. Girish Gadre | Dr. Sanvedya Kadam ^[2]

Abstract: Aim: The aimwas to study effects of intravitreal anti - vascular endothelial growth factor injection Avastin in posterior segment vasculopathies. Methods: In this prospective, single centre study, 79 eyes, including bilateral cases in age group 61 - 70 years of different posterior segment vasculopathies were given bevacizumab with dose of 1.25mg/0.05ml. post - operative vision was assessed, and OCT was done immediately and on follow up after 1 week, 4weeks. Results: Out of 79 eyes with age group 61 - 70 years, 58.67% of subjects were male and 34.67% of them were females respectively, majority were with PDR (28%) followed by BRVO (26%), CNVM (24%), CRVO (12%), ROP (6.67%), NG (1.33%) and wetARMD (1.33%) out of which there were 9 bilateral cases, 5 cases belong to PDR and intravitreal injection bilaterally was required while there were 4 bilateral active CNVM cases. majority of subjects had hypertension (41.42%) and diabetes mellitus (41.42%). Out of 5 babies 1 baby had respiratory distress. Majority of subjects had IOP 10 - 21 mm of Hg in right eye (97.14%) and left eye (92.86%) and majority of subjects had visual acuity <6/60 in right eye (58.57%) and left eye (51.43%). pre - injection. Pre - op mean OCT among subjects was 419.61. Post injection, 6/6 vision was achieved by 15 (18.99%) subjects 4 weeks later after injection AVASTIN, 19 Eyes required 2 doses of injection in CNVM (6.32%), followed by BRVO (5.06%), CRVO (2.53%), STBRVO (2.53%), ITBRVO (1.26%). Mean central macular thickness on OCT was 418.58, 333.21 and 304.32 at immediate, 1 week later and 4 week later after injection AVASTIN respectively. Conclusions: The present clinical prospective study undertaken to study effects of intravitreal anti VEGF injection Avastin in posterior segment vasculopathies concludes that Intravitreal bevacizumab application provides significant improvement in visual acuity of various posterior segment vasculopathies and may therefore be a promising approach in the primary treatment of posterior segment vasculopathies.

Keywords: Retinopathy, vasculopathy, bevacizumab, vascular endothelial growth factor

Edition: Volume 12 Issue 9, September 2023,

Pages: 752 - 756